25843 Tapinarof cream 1% once daily for plaque psoriasis: Patient-reported outcomes from two pivotal phase 3 trials

Psoriasis Patient ◽

Phase 3 ◽

Pivotal Phase ◽

Once Daily ◽

Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient‐reported outcomes from a Phase 3 study

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.13702 ◽

2016 ◽

Vol 30 (10) ◽

pp. 1753-1759 ◽

Cited By ~ 25

Author(s):

F. Valenzuela ◽

C. Paul ◽

L. Mallbris ◽

H. Tan ◽

J. Papacharalambous ◽

...

Keyword(s):

Plaque Psoriasis ◽

Psoriasis Patient ◽

Phase 3 ◽

Patient‐reported outcomes with risankizumab versus fumaric acid esters in systemic therapy‐naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.17109 ◽

2021 ◽

Author(s):

D Thaçi ◽

AM Soliman ◽

K Eyerich ◽

A Pinter ◽

M Sebastian ◽

...

Keyword(s):

Clinical Trial ◽

Fumaric Acid ◽

Plaque Psoriasis ◽

Systemic Therapy ◽

Phase 3 ◽

Severe Plaque Psoriasis ◽

Fumaric Acid Esters ◽

Patient Reported ◽

Acid Esters

25750 Tapinarof cream 1% once daily for plaque psoriasis: Secondary efficacy outcomes from two pivotal phase 3 trials

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.300 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB69

Author(s):

Linda Stein Gold ◽

Andrew Blauvelt ◽

April Armstrong ◽

Seemal R. Desai ◽

Howard Sofen ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase 3 ◽

Pivotal Phase ◽

Once Daily

Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.13808 ◽

2016 ◽

Vol 31 (2) ◽

pp. 323-332 ◽

Cited By ~ 9

Author(s):

C.E.M. Griffiths ◽

R. Vender ◽

H. Sofen ◽

L. Kircik ◽

H. Tan ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase 3 ◽

Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: DLQI and WPAI Patient-Reported Outcomes from an Ongoing Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT)

10.25251/skin.1.supp.2 ◽

2017 ◽

Vol 1 ◽

pp. s3 ◽

Cited By ~ 1

Author(s):

Vincent Piguet ◽

Andrew Blauvelt ◽

Daniel Burge ◽

Luke Peterson ◽

Janice Drew ◽

...

Keyword(s):

Plaque Psoriasis ◽

Certolizumab Pegol ◽

Controlled Study ◽

Phase 3 ◽

Patient Reported ◽

Ongoing Phase

Abstract Not Available Disclosure: Study supported by Dermira.

Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: DLQI and WPAI Patient-Reported Outcomes from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2)

10.25251/skin.1.supp.3 ◽

2017 ◽

Vol 1 ◽

pp. s4 ◽

Cited By ~ 1

Author(s):

Diamant Thaci ◽

Alice Gottlieb ◽

Kristian Reich ◽

Jerry Bagel ◽

Daniel Burge ◽

...

Keyword(s):

Plaque Psoriasis ◽

Certolizumab Pegol ◽

Phase 3 ◽

Patient Reported ◽

Ongoing Phase

Abstract Not Available Disclosure: Study supported by Dermira.

Durable Improvement in Patient Reported Outcomes across DLQI Subdomains Over 48 Weeks in Chronic Plaque Psoriasis Patients Treated with Certolizumab Pegol in Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)

10.25251/skin.3.2.15 ◽

2019 ◽

Vol 3 (2) ◽

pp. 175

Author(s):

A Blauvelt ◽

RB Warren ◽

K Reich ◽

Et Al.

Keyword(s):

Plaque Psoriasis ◽

Certolizumab Pegol ◽

Phase 3 ◽

Two Phase ◽

Abstract not available. Disclosures: Study sponsored by UCB.

Patient-reported outcomes in subjects with plaque psoriasis treated with tapinarof cream: Results from a phase 2b, randomized parallel-group study

10.25251/skin.2.supp.86 ◽

2018 ◽

Vol 2 ◽

pp. S85

Author(s):

Neal Bhatia ◽

David Rubenstein ◽

Anna M Tallman ◽

James Lee

Keyword(s):

Plaque Psoriasis ◽

Parallel Group Study ◽

Parallel Group ◽

Patient-Reported Outcomes from Two Randomized, Double-Blind, Vehicle-Controlled Phase 3 Trials in Axillary Hyperhidrosis (ATMOS-1 & ATMOS-2)

10.25251/skin.1.supp.95 ◽

2017 ◽

Vol 1 ◽

pp. s96

Author(s):

David M Pariser ◽

Adelaide A Hebert ◽

Janice Drew ◽

John Quiring ◽

Dee Anna Glaser

Keyword(s):

Axillary Hyperhidrosis ◽

Phase 3 ◽

Double Blind ◽

Abstract Not AvailableDisclosure: Study supported by Dermira.

Patient-Reported Outcomes from Two Randomized, Double-Blind, Vehicle Controlled Phase 3 Trials in Axillary Hyperhidrosis (ATMOS-1 & ATMOS-2)

10.25251/skin.2.supp.41 ◽

2018 ◽

Vol 2 ◽

pp. S41

Author(s):

David M Pariser ◽

Adelaide A Hebert ◽

Janice Drew ◽

John Quiring ◽

Dee Anna Glaser

Keyword(s):

Axillary Hyperhidrosis ◽

Phase 3 ◽

Double Blind ◽

Abstract not available. Disclosures: Study supported by Dermira. Copyright SKIN 2018